Denmark-based Novo Nordisk has received an exclusive worldwide licence to EpiDestiny's sickle cell disease programme, named EPI01, it was reported on Monday.

EpiDestiny is eligible to receive more than USD400m in upfront, development and sales milestone payments and will receive royalties on net sales.

Both parties will collaborate to develop EPI01 in sickle cell disease and beta-thalassaemia. EpiDestiny retains all rights to continue development of EPI01 in oncology. EPI01 is a novel, orally available, disease-modifying therapy to increase HbF and interrupt sickle cell disease pathophysiology.

Also, EpiDestiny has received Rare Pediatric Disease, Fast Track and Orphan Designations for EPI01 from the US Food and Drug Administration.